Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

Oncology Times - OncTimes Talk

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to three A non-small cell lung cancer.
In a late-breaking abstract reported at the 2023 American Society of Clinical Oncology Meeting Plenary Session, Herbst showed that osimertinib not only improved disease-free survival, but also brought a clear and big benefit in overall survival.